Although broad consensus exists in the scientific community that benzene is a leukemogen, there is considerable uncertainty regarding the actual shape of the exposure--response curve (ERC) ([@b12-ehp-118-526]; [@b28-ehp-118-526]). Most of the current epidemiologic evidence for an increased leukemia risk stems from studies among workers exposed to relatively high levels of benzene \[[@b25-ehp-118-526]; [@b46-ehp-118-526]\]. The risks of leukemia at lower benzene exposures, however, remain largely unclear. Importantly, exposure to benzene in occupational settings has dropped considerably during the last three decades ([@b9-ehp-118-526]). Furthermore, a large proportion of the general population is exposed to low levels of benzene (\< 0.2 ppm) through car exhaust, cigarette smoke, and other sources ([@b19-ehp-118-526]). Therefore, the primary interest of current benzene risk assessment is in risks associated with exposure to low levels of benzene.

In existing risk assessments of benzene, the ERC was assessed based on evidence from one "best" study or, alternatively, from a limited set of "best" studies ([@b25-ehp-118-526]; [@b46-ehp-118-526]). These investigations were mostly conducted among relatively highly exposed workers, so the derived ERC might not be directly applicable to workers exposed to lower levels or to the general population. Furthermore, these risk assessments used linear models to describe the ERC, but increasing evidence from molecular epidemiologic studies of workers exposed to a wide range of benzene levels indicates that the shape of the ERC for benzene and its toxic effects may be nonlinear. This hypothesis is based on the observation that the dose-related production of urinary metabolites of benzene, which include the toxic metabolites muconic acid and hydroquinone and the less toxic metabolites phenol and catechol, decreases with increasing benzene exposure ([@b20-ehp-118-526], [@b21-ehp-118-526]; [@b38-ehp-118-526]). Furthermore, some evidence shows that benzene metabolism favors the production of the toxic metabolites hydroquinone and muconic acid at low exposures ([@b20-ehp-118-526]). This is especially important because hydroquinone is the precursor of 1,4-benzoquinone, which is generally regarded as the most hematotoxic metabolite of benzene ([@b20-ehp-118-526]). The nonlinear production of benzene's toxic metabolites would have important consequences for risk assessment because one would expect this to result in a nonlinear relationship between benzene exposure and health outcomes as well. Indeed, in a study that looked at the shape of the dose--response curve of benzene-related hematologic effects, a sharper drop in the peripheral white blood cell count was observed at lower levels of exposure (\< 1 ppm) than at higher levels ([@b24-ehp-118-526], [@b23-ehp-118-526]).

To explore the shape of the benzene--leukemia ERC, we performed flexible meta-regressions on a set of studies that reported results from quantitative exposure--response analysis or benzene and leukemia. For our analyses, we used a modified version of the approach proposed by [@b3-ehp-118-526] that was applied to studies on alcohol and mortality and on silica and lung cancer ([@b22-ehp-118-526]). It consists of fitting a set of regression models that includes (flexible) regression splines and linear models to aggregated data, adjusting for the expected correlation of estimated (relative) risks within studies. An improvement of this approach over existing meta-regression methods is that the use of regression splines eliminates the need to make strict a priori assumptions regarding the shape of the ERC, which allows for a more objective evaluation of its actual shape.

Materials and Methods
=====================

Identification of studies and evaluation of study quality
---------------------------------------------------------

Publications eligible for the meta-regression were identified by a PubMed search that included the MESH key words "benzene," "humans," and "leukemia" in combination with either "cohort studies" or "case--control studies." Other publications were added by following references included in a literature review by [@b41-ehp-118-526] that was identified in the original PubMed search and in regulatory risk assessments by the Canadian Centre for Occupational Health and Safety, the U.S. National Institute for Occupational Safety and Health, the U.S. Agency for Toxic Substances and Disease Registry, and the U.S. EPA ([@b2-ehp-118-526]; [@b27-ehp-118-526]; [@b30-ehp-118-526]; [@b46-ehp-118-526]). The quality of the 11 studies that reported results from quantitative exposure--response analysis for benzene and leukemia (mortality or incidence) was evaluated using a previously developed evaluation framework ([@b47-ehp-118-526]). The first tier of the framework consisted of six criteria that are related to crucial aspects of the quality of the design, the quality of conduct, and the quality of the reporting of human observational studies \[see Supplemental Material (doi:10.1289/ehp.0901127)\]. A study was excluded from the meta-regression if it did not meet all of the six criteria. Nine studies were of sufficient quality to be included in the meta-regression ([Table 1](#t1-ehp-118-526){ref-type="table"}). Two studies that reported results from quantitative exposure--response analysis were excluded: One expressed exposure in undefined units ([@b16-ehp-118-526]), and the other provided insufficient details that resulted in a lack of insight regarding the decisions made in the statistical analysis ([@b10-ehp-118-526]).

Extraction of data from the incorporated studies
------------------------------------------------

A database was constructed based on published data available for the studies incorporated in the meta-regression. We extracted only risk estimates reported for cumulative exposure to benzene (expressed in ppm-years or ppm-months). The database contained the following fields: study identifier, study design, exposure category, risk estimate, confidence interval for the risk estimate, and number of cases and controls for each exposure category (nested case--control studies) or the size of the study population for the exposure category (cohort studies). Three different epidemiologic study designs contributed to the current meta-regression: the nested case--control design (*n* = 3), the cohort design with an internal reference population (*n* = 1), and the cohort design with an external reference population (*n* = 5; [Table 1](#t1-ehp-118-526){ref-type="table"}). Reported odds ratios (ORs), relative risks (RRs), and standardized mortality ratios (SMRs) were combined and interpreted as estimates of the RR for the purpose of this meta-regression ([@b26-ehp-118-526]). The studies selected for the meta-regression were also different with regard to the definition of the reference population that was used. The cohort studies assumed "background (environmental) exposure" in their reference populations ([@b6-ehp-118-526]; [@b11-ehp-118-526]; [@b18-ehp-118-526]; [@b35-ehp-118-526]; [@b45-ehp-118-526]; [@b49-ehp-118-526]). Typical daily environmental exposure to benzene can range up to 0.2 ppm, which, over a 70-year life span, accumulates to a maximum of 14 ppm-years of cumulative exposure ([@b19-ehp-118-526]). In the nested case--control studies, individuals in the lowest exposure category were used as the reference population (ranging from \< 0.17 ppm-years to \< 1 ppm-years occupational exposure) ([@b14-ehp-118-526]; [@b39-ehp-118-526]; [@b40-ehp-118-526]).

Preparation of the data extracted from the publications
-------------------------------------------------------

Three steps were necessary to prepare the extracted data for use in the meta-regression models. In the first step, we assigned a specific cumulative exposure estimate to each risk estimate. It is common practice to report only the boundaries of the exposure categories used in an exposure--response analysis, and this was the case for all included studies except the Swaen study, which reported an average mean exposure ([@b15-ehp-118-526]; [@b45-ehp-118-526]). To estimate the mean exposure for the assigned exposure categories, we assumed a log-normal distribution for the cumulative exposure for each study. Any data providing information on the exposure distribution within a study were collected from the publication (i.e., the number of person-years per exposure category, the number of controls per exposure category, or the number of expected cases per exposure category). Maximum likelihood estimation was used to fit a probability density function (PDF) to the available data. Using the PDF, we assigned an average cumulative exposure to each exposure category based on its respective boundaries. To avoid unreasonably high estimates of the average exposure in the highest exposure group, we truncated the exposure distribution at the maximum reported cumulative exposure level. This method of assigning specific cumulative exposures is similar to the approach that was proposed by [@b17-ehp-118-526].

In the second step, we estimated the variance of each specific risk estimate to allow weighting based on the precision of the risk estimates in the meta-regression ([@b13-ehp-118-526]). The variance of RRs and ORs was estimated using the reported confidence intervals following a method discussed by [@b37-ehp-118-526]. Estimated variances for studies that reported asymmetrical confidence intervals on the log scale were based on the upper confidence limit only ([@b7-ehp-118-526]; [@b48-ehp-118-526]).

In the third step, we estimated the covariance between the different risk estimates within a study by applying the approach advocated by [@b42-ehp-118-526]. This approach is necessary because risk estimates of a study based on a common internal reference group will be correlated. Ignoring this correlation in the meta-regression underestimates the variance of the risk estimates from the study that results in an overestimation of its weight ([@b3-ehp-118-526]; [@b15-ehp-118-526]). The Canada-Petrol study ([@b40-ehp-118-526]) lacked the information necessary to estimate the covariance matrix; therefore, uncorrected variances were used for this study. For studies that reported SMRs, we did not estimate covariance because SMRs within a single study can be assumed to be largely independent when the expected number of deaths used to calculate the SMRs is based on a sufficiently large population.

Application of the (regression) models to describe the exposure--response relation
----------------------------------------------------------------------------------

Natural spline models (with knots at the 20th, 50th, and 80th percentiles) as well as linear models were fitted to the data to investigate the shape of the exposure--response relation. To improve the statistical properties of the regression models, we fitted all models to the natural logarithm of the reported risk estimates ([@b4-ehp-118-526]). Regression models were fitted to the data using a modified version of a macro developed by [@b3-ehp-118-526]. All regression models allowed for (random) study-specific intercepts and exposure effects to accommodate potential between-study heterogeneity ([@b13-ehp-118-526]). Model deviance was used to compare goodness of fit between (nested) models.

Sensitivity analyses
--------------------

For two cohort studies Pliofilm ([@b35-ehp-118-526]) and Dow ([@b6-ehp-118-526]) multiple updates were available ([Table 1](#t1-ehp-118-526){ref-type="table"}). These updates represent multiple reports on the same cohort. In the most recent report, researchers had the opportunity to follow the participants for the longest time since the start of the follow-up period.For these cohorts, the most recent update was included in the meta-regression. To assess the impact of varying follow-up times in our analysis, we also conducted the meta-regression with risk estimates that were abstracted from earlier updates of the Pliofilm and Dow cohorts ([@b8-ehp-118-526]; [@b36-ehp-118-526]). Substitution of the risk estimates did not have a substantial effect on the shape of the predicted ERC or on model fit to the data (data not shown). Sensitivity of the predicted ERC to the inclusion of specific studies was assessed with a jackknifing analysis, excluding one study at a time before (re)predicting the exposure--response relation. In addition, we analyzed the cohort studies (including those with an external reference group as well as the single study with an internal reference group) and nested case--control studies separately and compared their ERC predictions. To allow flexible prediction of the ERC, all sensitivity analyses were done using natural splines.

Prediction of risk estimates
----------------------------

Benzene--leukemia ERC RRs were estimated for four plausible scenarios at three different levels of cumulative exposure (10, 20, and 40 ppm-years, corresponding to 0.25, 0.5, and 1 ppm intensity of exposure over a tenure of 40 years). We used fitted regression models to predict the risk estimates with associated confidence intervals. In addition, corrected risk estimates and confidence intervals were calculated by subtracting the intercept at zero exposure predicted by the regression model from the risk estimates.

Software
--------

Average exposure levels for reported exposure categories were estimated using R, version 2.7 (R Core Development Group, Vienna, Austria). All other statistical analyses were performed using SAS software for Windows (version 9.1, SAS Institute Inc., Cary, NC, USA).

Results
=======

Nine studies had sufficient quality to be included in the meta-regression. All included studies were performed in the occupational setting. Together, these studies provided 30 risk estimates over a range of 0.32--554.3 (assigned) ppm-years ([Figure 1A](#f1-ehp-118-526){ref-type="fig"}). Nineteen (63%) of the risk estimates were assigned a cumulative exposure \< 50 ppm-years ([Figure 1B](#f1-ehp-118-526){ref-type="fig"}). Most of the risk estimates for the lower exposure range were provided by nested case--control studies. The differences in exposure levels between studies can be largely attributed to the different industries in which the studies were performed. The nested case--control studies were all performed in the petroleum industry, whereas the cohort studies were performed in the chemical industry (Pliofilm, Dow, Wong, and Swaen studies), in a shoe factory (Costantini study), or a wide range of different industries \[Chinese Academy of Preventive Medicine--National Cancer Institute (CAPM-NCI) study\] ([@b18-ehp-118-526]; [Table 1](#t1-ehp-118-526){ref-type="table"}).

Predictions of the ERC based on a natural spline model and a linear model are presented in [Figure 2](#f2-ehp-118-526){ref-type="fig"}. The lower deviance of the natural spline (deviance = 25.84, 27 df) compared with that of the linear model (deviance = 29.25, 28 df) suggests a slightly better fit \[chi square test (1 df), *p* = 0.06\]. The natural spline model also indicates a strong supralinear shape of the ERC in the low-exposure region, resulting in a considerable lower intercept than the linear model (RR = 1.33 vs. 1.65).

Results from a jackknifing analysis ([Figure 3](#f3-ehp-118-526){ref-type="fig"}) suggest that the Pliofilm and the CAPM-NCI studies were particularly influential for the (high-exposure region of the) predicted ERC. Exclusion of the Pliofilm study from the meta-regression resulted in a strong reduction of risks predicted for cumulative exposures \> 100 ppm-years, whereas exclusion of the CAPM-NCI study had the opposite effect. Exclusion of other studies had little impact on the predicted ERC.

Stratified analyses showed that study design had a considerable impact on the predicted ERC ([Figure 4](#f4-ehp-118-526){ref-type="fig"}). The ERC based on the cohort studies had a similar shape compared with the ERC based on the full data. However, the supralinear shape was somewhat less pronounced and the predicted intercept slightly lower (RR = 1.13 vs. 1.33). The deviance of the natural spline model fitted to the cohort studies was smaller than the deviance of the corresponding linear model \[deviance = 8.43 and 11.97 respectively; chi square test (1 df), *p* = 0.06\]. The analysis based on the three nested case--control studies resulted in extremely wide confidence intervals around the predicted ERC and was essentially uninformative ([Figure 4](#f4-ehp-118-526){ref-type="fig"}).

We predicted the RRs for leukemia for three cumulative exposure levels (10, 20, 40 ppm-years) based on four different modeling scenarios for the shape of the benzene leukemia ERC ([Table 2](#t2-ehp-118-526){ref-type="table"}). The four scenarios were a natural spline with intercept fitted to all studies (scenario A), a natural spline without intercept fitted to all studies (scenario B), a natural spline with intercept fitted to the cohort studies (scenario C), and a linear model without intercept fitted to all studies (scenario D1) or only the cohort studies (scenario D2; [Figure 5](#f5-ehp-118-526){ref-type="fig"}). Scenario A predicted the highest RRs (1.52, 1.73, and 2.11 for cumulative exposures of 10, 20, and 40 ppm-years respectively), although these dropped considerably (RR = 1.14, 1.29, and 1.59) after correction for the predicted intercept. RRs predicted in scenario B (RR = 1.22, 1.46, and 1.96) were somewhat lower than the uncorrected RRs from scenario A. Predictions using data from the cohort studies only (scenario C) were also lower than those predicted by scenario A (all studies) (RR = 1.25, 1.38, 1.67), although these differences largely disappeared after we corrected for the intercept. Finally, predictions of the RRs based on scenario D1 (RR = 1.04, 1.09, 1.19) and D2 (RR = 1.05, 1.10, 1.20) were very similar and considerably lower than the predictions based on the other scenarios.

Discussion
==========

Interpretation of the predicted ERC
-----------------------------------

We presented estimates of the benzene--leukemia ERC based on predictions from two regression models. Both the natural spline and linear regression models indicated a positive relation between cumulative exposure to benzene and leukemia risk, although risk appeared to increase more strongly at low exposures in the natural spline model. This supralinear shape of the natural spline model at low exposures is consistent with the increasing evidence that saturable metabolism plays an important role in the low-dose carcinogenicity of benzene ([@b20-ehp-118-526], [@b21-ehp-118-526]; [@b23-ehp-118-526]; [@b32-ehp-118-526], [@b34-ehp-118-526], [@b33-ehp-118-526], [@b31-ehp-118-526]; [@b38-ehp-118-526]).

Alternative explanations for the nonlinear relation between (inhalatory) benzene exposure and leukemia that we found are depletion of susceptible individuals at high benzene exposure levels and bias due to attenuation of the exposure--response relation within or between studies ([@b43-ehp-118-526]). Attenuation of exposure--response relations is commonly observed in occupational studies and can be caused by several factors, including the healthy worker survivor effect, high disease background rates, exposure measurement error, and confounding and effect modification ([@b43-ehp-118-526]). However, not all of these factors are equally likely to have played a role in occupational studies on benzene and leukemia. Confounding should be considered a potential factor that might have introduced attenuation, but none of the included studies demonstrated (or was able to demonstrate) a confounding effect from potential confounders such as ionizing radiation, smoking, and family history of leukemia ([@b52-ehp-118-526]). In addition, it is unlikely that these factors could have caused serious distortion of the study findings considering the general lack of association with exposure to benzene across the assessed industries (ionizing radiation), weak association with leukemia (smoking), and rare occurrence (family history of leukemia) ([@b52-ehp-118-526]).

Factors that contributed to the heterogeneity observed between studies were differences in study design and exposure assessment. Although all studies were comparable regarding the context of exposure (occupational exposure), considerable differences exist in the geographical location, type of industry, and intensity and frequency of exposure to benzene ([Table 1](#t1-ehp-118-526){ref-type="table"}). Differences in study design resulted in different types of risk estimates that were reported: RRs, ORs, and SMRs ([Table 1](#t1-ehp-118-526){ref-type="table"}). However, ORs and SMRs can be interpreted as reasonable approximations of the RR when the disease is rare, and these measures have been pooled with RRs for meta-analysis in previous analyses ([@b26-ehp-118-526]; [@b44-ehp-118-526]). According to our evaluation, the quality of exposure assessment was sufficient in all included studies ([@b47-ehp-118-526]). However, systematic differences in exposure assessment strategies between studies might have contributed to the between-study heterogeneity. Because all included studies assessed exposure retrospectively based on a relatively limited set of exposure measurements, exposure estimation in these studies was based partly on decision rules to extrapolate exposure measurements to time periods and exposure circumstances for which no measurements were available ([@b6-ehp-118-526]; [@b11-ehp-118-526]; [@b14-ehp-118-526]; [@b18-ehp-118-526]; [@b35-ehp-118-526]; [@b39-ehp-118-526]; [@b40-ehp-118-526]; [@b45-ehp-118-526]; [@b49-ehp-118-526]). The significant amount of expert judgment that goes into these decision rules makes it conceivable that systematic differences in exposure assessment may exist between studies. This situation is illustrated by the exposure assessment for the Pliofilm cohort where three groups of authors have published three different sets of exposure estimates, based on the same exposure measurement data ([@b12-ehp-118-526]; [@b29-ehp-118-526]; [@b36-ehp-118-526], [@b35-ehp-118-526]). In contrast, the three nested case--control studies attempted to limit systematic error in exposure assessment by applying similar exposure assessment approaches ([@b14-ehp-118-526]; [@b39-ehp-118-526]; [@b40-ehp-118-526]).

We tried to assess the potential impact of between-study heterogeneity in the sensitivity analyses. Visual inspection of the results from a jackknifing analysis ([Figure 3](#f3-ehp-118-526){ref-type="fig"}) showed that two studies that provided risk estimates for the highest assigned cumulative exposures had a considerable impact on the ERC for the higher exposure range. The impact on the lower exposure range was less pronounced. Exclusion of the Australian Health Watch (AHW; [@b1-ehp-118-526]; [@b14-ehp-118-526]) study, which reported relatively high risks for the low-exposure range ([Figure 1](#f1-ehp-118-526){ref-type="fig"}), had little impact on the shape of the ERC. Results from the sensitivity analysis stratified by study design indicated considerable differences between the ERC based on the nested case--control studies from the petroleum industry and the ERC based on the cohort studies. The shape of the ERC based on the cohort studies only was similar to the shape of the ERC based on all studies. Although the shape of the ERC for the nested case--control studies could be estimated only very imprecisely, the results indicated that these studies were largely responsible for the rather high intercepts that were predicted for the ERCs based on the full data.

Assessing publication bias in a flexible meta-regression is complicated because no standard statistical approaches are available to deal with the correlated effect estimates and the nonlinear exposure--response relations. However, in our opinion it is unlikely that studies with quantitative benzene exposure estimates would not have reported risk estimates for leukemia even if these had been negative because this is one of the major cancer outcomes associated with the exposure. Also, considering the large effort that is required to generate quantitative benzene exposure estimates, it is improbable that any study that had quantitative exposure estimates available would not have been published at all.

Considering that risk estimates in the included studies were calculated in reference to populations with assumed no or negligible occupational exposure to benzene, one might have expected a predicted marginal intercept (ln RR) of approximately 0 (RR = 1) at 0 ppm-years. Although intercepts above 0 are frequently observed in exposure--response studies based on epidemiologic data, most other meta-regression studies have avoided the issue by forcing their regression models to fit through the origin ([@b3-ehp-118-526]; [@b15-ehp-118-526]). We did include intercepts in our regression models to attain the best possible fit to the data, which resulted in intercepts of RRs of 1.33 and 1.65 in the natural spline and linear regression models, respectively. An explanation for these nonzero intercepts may be the lack of risk estimates for very low exposure levels (\< 0.32 ppm-year). Risk estimates at slightly higher, but still very low, exposure levels (ppm-years) already indicate a strong increase in risk. A natural spline, being linear in its tails, may be unable to track the curvature of the ERC at these low levels, resulting in a nonzero intercept. The same reasoning would apply to intercepts from the linear model, although the effect may be even more extreme. However we cannot exclude the effect of lower-than-expected leukemia risk in the reference populations or (conversely) higher nonbenzene-related leukemia risk in the exposed populations. Finally, attenuation of the ERC due to random and systematic error in the exposure assessment might also have forced the intercept up ([@b5-ehp-118-526]; [@b43-ehp-118-526]).

Implications of the findings for quantitative risk assessment (QRA)
-------------------------------------------------------------------

To facilitate the use of our meta-regression results in QRA, we provided the benzene leukemia ERC for three plausible scenarios ([Figure 5](#f5-ehp-118-526){ref-type="fig"}, [Table 2](#t2-ehp-118-526){ref-type="table"}). In scenario A, the natural spline model was used, which fitted the data slightly better than a linear model. However, the estimate of leukemia risk at 0 ppm-years (the intercept) for this model was much lower than that for the linear model. Because application of these models for risk assessment purposes will most likely entail subtraction of the intercept from all predictions \[effectively lowering the predicted (increased) risks for benzene at each exposure level\], we favor scenario A ([Figure 5A](#f5-ehp-118-526){ref-type="fig"}) for risk prediction over the alternatives ([Table 2](#t2-ehp-118-526){ref-type="table"}). If one believes that the intercept is due to the natural spline failing to track the shape of the ERC at very low exposures, one may prefer predictions from a spline model without an intercept, thus forcing the predicted ERC through the origin (scenario B, [Figure 5B](#f5-ehp-118-526){ref-type="fig"}). This model fitted the data only slightly worse than scenario A and may therefore be considered a plausible alternative \[chi-square test (1 df), *p* = 0.11\]. If one believes that the nested case--control studies should not be used for prediction of the ERC, scenario C ([Figure 5C](#f5-ehp-118-526){ref-type="fig"}) could be used, which was based on a natural spline model with an intercept fitted to data from the cohort studies only. This scenario resulted in slightly lower predicted risks for exposures \< 100 ppm-years. Finally, scenarios D1 (all studies, [Figure 5D](#f5-ehp-118-526){ref-type="fig"}) and D2 (cohort studies only) were based on linear models without an intercept and are therefore similar in spirit to models commonly used in QRA ([@b25-ehp-118-526]; [@b46-ehp-118-526]) ([Figure 5](#f5-ehp-118-526){ref-type="fig"}). Clearly, these models fitted the data clearly worse than did the relevant alternative models in scenario A \[chi-square test (2 df), *p* = 0.002\] and scenario C chi-square test (2 df), *p* = 0.02\].

To compare predictions from scenarios A--D with predictions from existing QRAs, we estimated RRs for three cumulative exposures in the low exposure range (10, 20, and 40 ppm-years; [Table 2](#t2-ehp-118-526){ref-type="table"}). This showed that risk estimates from our models at these exposures are very similar to those based on the (multiplicative) models used by the U.S. EPA and the California Environmental Protection Agency in their QRA of benzene ([@b25-ehp-118-526]; [@b46-ehp-118-526]). However, although these QRAs were based on data from either the Pliofilm study or the CAPM-NCI study, our approach allowed us to use all available epidemiologic evidence to date and should therefore be more robust. In addition, our approach allowed for a nonlinear shape of the ERC to be used in QRA, which appears to be more appropriate. It is important to note that all analyses were performed on the overarching disease outcome "leukemia." Slight differences in the definition of this disease existed between studies ([Table 1](#t1-ehp-118-526){ref-type="table"}). Unfortunately, analyses for specific subtypes of leukemia will be hampered by a lack of data.

Conclusion
==========

Flexible meta-regression of the aggregated risk estimates from a set of occupational human observational studies offers an efficient approach to acquiring more insight in the functional relation between exposure to benzene and leukemia. The flexible meta-regression model predicted a supralinear shape of the ERC. Although the limited number of available studies and the large heterogeneity between studies were considerable limitations, sensitivity analyses demonstrated that results were not strongly affected. Our application of a flexible meta-regression method provides the most comprehensive evaluation of the benzene--leukemia ERC to date.

Supplemental Material is available online (doi:10.1289/ehp.0901127 via <http://dx.doi.org/>).

We thank V. Bagnardi for providing his macro "Flexible." The macro used in this study is available from J.V. on request.

This work was performed as part of the work package "integrated risk assessment" of the Environmental Cancer Risk, Nutrition and Individual Susceptibility Network of Excellence, operating within the European Union 6th Framework Program, Priority 5: "Food Quality and Safety" (FOOD-CT-2005-513943).

![Scatter plot of the risk estimates extracted from the nine studies included in the meta-regression, based on the assigned average cumulative exposure: Full range of cumulative exposures (*A*) and cumulative exposures \< 50 ppm-years (*B*). AHW, Australian Health Watch.](ehp-118-526f1){#f1-ehp-118-526}

![Predicted ERC using all risk estimates from the nine included studies based on a natural spline and linear regression model. Plot 1 is the predicted ERC based on a linear model. Plot 2 is the predicted ERC based on a natural spline model (knots are located at 2.9, 22.7, and 125.5 ppm-years). Dashed lines represent the 95% CIs of the predictions. Rug plot indicates the distribution of the estimated cumulative exposure for each risk estimate included in the analyses.](ehp-118-526f2){#f2-ehp-118-526}

![Sensitivity analysis on the prediction of the ERC based on a natural spline. Graph represents nine plots of the predicted ERC based on all studies minus one. The plots are identified by the study that was excluded: 1, CAPM-NCI; 2, Dow; 3, Costantini; 5, US-Chemical ([@b49-ehp-118-526]); 6, Swaen; 7, Canada-Petrol; 8, AHW; 9, UK-Petrol; and 10, Pliofilm. Plot 4 is the predicted ERC based on all available studies (blue line). Abbreviation: AHW, Australian Health Watch.](ehp-118-526f3){#f3-ehp-118-526}

![Predicted ERC stratified by study design based on a natural spline. Plot 1 is the predicted ERC based on only the nested case--control studies (knots are located at 1.0, 2.9, and 18.1 ppm-years). Plot 2 is the predicted ERC based on only the cohort studies (knots are located at 13.1, 67.1, and 277.6 ppm-years). Dashed lines represent the 95% CIs of the predictions.](ehp-118-526f4){#f4-ehp-118-526}

![Four different scenarios for the shape of the benzene--leukemia ERC: Natural spline with intercept fitted to all studies (best-fitting model) (*A*), natural spline without intercept fitted to all studies (*B*), natural spline with intercept fitted to the cohort studies (*C*), and linear model without intercept (*D*) fitted to all the studies (1) and only the cohort studies (2). Dashed lines are 95% CIs.](ehp-118-526f5){#f5-ehp-118-526}

###### 

Details of the studies included in the meta-regression.

  Reference (study)                                                          Study design           Risk estimates   Country       Industry                Reference category                                                       Exposure category (ppm-years)   Study outcome   ICD code (revision)[b](#tfn3-ehp-118-526){ref-type="table-fn"}   Study population size                                 
  -------------------------------------------------------------------------- ---------------------- ---------------- ------------- ----------------------- ------------------------------------------------------------------------ ------------------------------- --------------- ---------------------------------------------------------------- ----------------------------------------------------- --------------------------------------------
  [@b49-ehp-118-526]                                                         Cohort                 SMR              USA           Chemical industry       National population death rates                                          \< 15                           ≥ 60            Mortality                                                        204--207 (8)                                          7,676 individuals, 6 cases
                                                                                                                                                                                                                                                                                                                                                                                                           
  [@b18-ehp-118-526] (CAPM-NCI)[c](#tfn4-ehp-118-526){ref-type="table-fn"}   Cohort                 RR               China         Variety of industries   Workers employed in work units or factories where benzene was not used   \< 40                           \> 100          Incidence                                                        204--208 (9)                                          74,828 exposed, 35,805 unexposed, 47 cases
                                                                                                                                                                                                                                                                                                                                                                                                           
  [@b35-ehp-118-526] (Pliofilm)                                              Cohort                 SMR              USA           Chemical industry       National population death rates                                          0.01--40                        \> 400          Mortality                                                        204--208[d](#tfn5-ehp-118-526){ref-type="table-fn"}   1,291 individuals, 15 cases
                                                                                                                                                                                                                                                                                                                                                                                                           
  [@b11-ehp-118-526]                                                         Cohort                 SMR              Italy         Shoe factory            National and regional specific death rates                               \< 40                           \> 200          Mortality                                                        204--207 (8)                                          1,687 individuals, 11 cases
                                                                                                                                                                                                                                                                                                                                                                                                           
  [@b6-ehp-118-526] (Dow)                                                    Cohort                 SMR              USA           Chemical industry       National and regional specific death rates                               \< 28.3                         \> 79.1         Mortality                                                        204--208 (9)                                          2,266 individuals, 12 cases
                                                                                                                                                                                                                                                                                                                                                                                                           
  [@b45-ehp-118-526][e](#tfn6-ehp-118-526){ref-type="table-fn"}              Cohort                 SMR              Netherlands   Chemical industry       National population death rates                                          3.4                             401.5           Mortality                                                        NA[f](#tfn7-ehp-118-526){ref-type="table-fn"}         311 individuals, 1 case
                                                                                                                                                                                                                                                                                                                                                                                                           
  [@b40-ehp-118-526] (Canada Petrol)                                         Nested case--control   OR               Canada        Petroleum industry      Workers exposed to \< 0.17 ppm-years                                     0.18--0.49                      8--219.8        Incidence                                                        204--207 (8)                                          14 cases, 55 controls
                                                                                                                                                                                                                                                                                                                                                                                                           
  [@b39-ehp-118-526] (UK-Petrol)                                             Nested case--control   OR               UK            Petroleum industry      Workers exposed to \< 0.26 ppm-years                                     0.26--0.59                      \> 4.79         Mortality/incidence                                              204--208 (9)                                          90 cases, 354 controls
                                                                                                                                                                                                                                                                                                                                                                                                           
  [@b1-ehp-118-526]; [@b14-ehp-118-526] (AHW)                                Nested case--control   OR               Australia     Petroleum industry      Workers exposed to ≤ 1 ppm-years                                         1--2                            \> 16           Incidence                                                        204--208 (9)                                          33 cases, 165 controls

Abbreviations: AHW, Australian Health Watch; CAPM-NCI, Chinese Academy of Preventive Medicine--National Cancer Institute; NA, not applicable; OR, odds ratio; RR, relative risk; SMR, standardized mortality ratio; UK, United Kingdom.

Lowest exposure category for which a risk estimate was reported (excluding reference category).

*International Classification of Diseases* (ICD) used for disease outcomes related to "leukemia": 204, lymphoid leukemia; 205, myeloid leukemia; 206, monocytic leukemia; 207, other specified leukemia; 208, leukemia of unspecified cell type \[[@b50-ehp-118-526], [@b51-ehp-118-526]\].

Study with internal reference group.

ICD code for "leukemia" category in effect at time of death of the cases.

Average mean exposure for tertiles of the exposure distribution; because of a lack of observed cases, a risk estimate was reported only for the middle tertile.

Disease categorization based on the Dutch electronic file of causes of death.

###### 

Comparison of predicted RRs for three cumulative exposure levels.

                                                                                   RR (95% CI)                             
  ----------------------------------------------- ------------ ------------------- ------------------- ------------------- -------------------
  Prediction meta-regression---all studies                                                                                 
   Scenario A: natural spline                     25.84 (27)   1.33 (0.87--2.05)   1.52 (1.08--2.15)   1.73 (1.27--2.34)   2.11 (1.51--2.96)
   Scenario A corrected for intercept                                              1.14 (1.04--1.26)   1.29 (1.07--1.56)   1.59 (1.15--2.19)
   Scenario B: natural spline without intercept   28.39 (28)   NA                  1.22 (1.11--1.34)   1.46 (1.22--1.75)   1.96 (1.44--2.68)
   Scenario D1: linear model without intercept    38.67 (29)   NA                  1.05 (1.02--1.07)   1.10 (1.05--1.15)   1.20 (1.09--1.32)
  Prediction meta-regression---cohort studies                                                                              
   Scenario C: natural spline                     8.43 (15)    1.13 (0.71--1.81)   1.25 (0.83--1.88)   1.38 (0.96--1.97)   1.67 (1.22--2.27)
   Scenario C corrected for intercept                                              1.10 (1.04--1.17)   1.22 (1.09--1.36)   1.48 (1.19--1.83)
   Scenario D2: linear model without intercept    15.95 (17)   NA                  1.04 (1.02--1.07)   1.09 (1.04--1.14)   1.19 (1.09--1.31)

NA, not applicable.
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